Academic Journal
Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis
| العنوان: | Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis |
|---|---|
| المؤلفون: | Ruslami, R., Gafar, F., Yunivita, V., Parwati, I., Ganiem, A.R, Aarnoutse, R.E., Wilffert, B., Alffenaar, J.C., Nataprawira, H.M. |
| المصدر: | Archives of Disease in Childhood, 107, 1, pp. 70-77 |
| سنة النشر: | 2022 |
| المجموعة: | Radboud University: DSpace |
| مصطلحات موضوعية: | Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences |
| الوصف: | Contains fulltext : 249114.pdf (Publisher’s version ) (Open Access) ; OBJECTIVE: To assess the pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents with tuberculous meningitis (TBM). DESIGN: Prospective observational pharmacokinetic study with an exploratory pharmacokinetic/pharmacodynamic analysis. SETTING: Hasan Sadikin Hospital, Bandung, Indonesia. PATIENTS: Individuals aged 0-18 years clinically diagnosed with TBM and receiving first-line anti-tuberculosis drug dosages according to revised WHO-recommended treatment guidelines. INTERVENTIONS: Plasma and cerebrospinal fluid (CSF) concentrations of isoniazid, rifampicin and pyrazinamide were assessed on days 2 and 10 of treatment. MAIN OUTCOME MEASURES: Plasma exposures during the daily dosing interval (AUC(0-24)), peak plasma concentrations (C (max)) and CSF concentrations. RESULTS: Among 20 eligible patients, geometric mean AUC(0-24) of isoniazid, rifampicin and pyrazinamide was 18.5, 66.9 and 315.5 hour∙mg/L on day 2; and 14.5, 71.8 and 328.4 hour∙mg/L on day 10, respectively. Large interindividual variabilities were observed in AUC(0-24) and C (max) of all drugs. All patients had suboptimal rifampicin AUC(0-24) for TBM treatment indication and very low rifampicin CSF concentrations. Four patients developed grade 2-3 drug-induced liver injury (DILI) within the first 4 weeks of treatment, in whom anti-tuberculosis drugs were temporarily stopped, and no DILI recurred after reintroduction of rifampicin and isoniazid. AUC(0-24) of isoniazid, rifampicin and pyrazinamide along with C (max) of isoniazid and pyrazinamide on day 10 were higher in patients who developed DILI than those without DILI (p<0.05). CONCLUSION: Higher rifampicin doses are strongly warranted in treatment of children and adolescents with TBM. The association between higher plasma concentrations of isoniazid, rifampicin and pyrazinamide and the development of DILI needs confirmatory studies. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| Relation: | https://repository.ubn.ru.nl//bitstream/handle/2066/249114/249114.pdf; https://repository.ubn.ru.nl/handle/2066/249114; https://doi.org/10.1136/archdischild-2020-321426 |
| DOI: | 10.1136/archdischild-2020-321426 |
| الاتاحة: | https://repository.ubn.ru.nl//bitstream/handle/2066/249114/249114.pdf https://repository.ubn.ru.nl/handle/2066/249114 https://doi.org/10.1136/archdischild-2020-321426 |
| رقم الانضمام: | edsbas.3FFF75E7 |
| قاعدة البيانات: | BASE |
| ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.3FFF75E7 868 3 Academic Journal academicJournal 867.599182128906 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.3FFF75E7&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://repository.ubn.ru.nl//bitstream/handle/2066/249114/249114.pdf# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Ruslami%2C+R%2E%22">Ruslami, R.</searchLink><br /><searchLink fieldCode="AR" term="%22Gafar%2C+F%2E%22">Gafar, F.</searchLink><br /><searchLink fieldCode="AR" term="%22Yunivita%2C+V%2E%22">Yunivita, V.</searchLink><br /><searchLink fieldCode="AR" term="%22Parwati%2C+I%2E%22">Parwati, I.</searchLink><br /><searchLink fieldCode="AR" term="%22Ganiem%2C+A%2ER%22">Ganiem, A.R</searchLink><br /><searchLink fieldCode="AR" term="%22Aarnoutse%2C+R%2EE%2E%22">Aarnoutse, R.E.</searchLink><br /><searchLink fieldCode="AR" term="%22Wilffert%2C+B%2E%22">Wilffert, B.</searchLink><br /><searchLink fieldCode="AR" term="%22Alffenaar%2C+J%2EC%2E%22">Alffenaar, J.C.</searchLink><br /><searchLink fieldCode="AR" term="%22Nataprawira%2C+H%2EM%2E%22">Nataprawira, H.M.</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Archives of Disease in Childhood, 107, 1, pp. 70-77 ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2022 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => Radboud University: DSpace ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Radboudumc+4%3A+lnfectious+Diseases+and+Global+Health+RIHS%3A+Radboud+Institute+for+Health+Sciences%22">Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Contains fulltext : 249114.pdf (Publisher’s version ) (Open Access) ; OBJECTIVE: To assess the pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents with tuberculous meningitis (TBM). DESIGN: Prospective observational pharmacokinetic study with an exploratory pharmacokinetic/pharmacodynamic analysis. SETTING: Hasan Sadikin Hospital, Bandung, Indonesia. PATIENTS: Individuals aged 0-18 years clinically diagnosed with TBM and receiving first-line anti-tuberculosis drug dosages according to revised WHO-recommended treatment guidelines. INTERVENTIONS: Plasma and cerebrospinal fluid (CSF) concentrations of isoniazid, rifampicin and pyrazinamide were assessed on days 2 and 10 of treatment. MAIN OUTCOME MEASURES: Plasma exposures during the daily dosing interval (AUC(0-24)), peak plasma concentrations (C (max)) and CSF concentrations. RESULTS: Among 20 eligible patients, geometric mean AUC(0-24) of isoniazid, rifampicin and pyrazinamide was 18.5, 66.9 and 315.5 hour∙mg/L on day 2; and 14.5, 71.8 and 328.4 hour∙mg/L on day 10, respectively. Large interindividual variabilities were observed in AUC(0-24) and C (max) of all drugs. All patients had suboptimal rifampicin AUC(0-24) for TBM treatment indication and very low rifampicin CSF concentrations. Four patients developed grade 2-3 drug-induced liver injury (DILI) within the first 4 weeks of treatment, in whom anti-tuberculosis drugs were temporarily stopped, and no DILI recurred after reintroduction of rifampicin and isoniazid. AUC(0-24) of isoniazid, rifampicin and pyrazinamide along with C (max) of isoniazid and pyrazinamide on day 10 were higher in patients who developed DILI than those without DILI (p<0.05). CONCLUSION: Higher rifampicin doses are strongly warranted in treatment of children and adolescents with TBM. The association between higher plasma concentrations of isoniazid, rifampicin and pyrazinamide and the development of DILI needs confirmatory studies. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => unknown ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://repository.ubn.ru.nl//bitstream/handle/2066/249114/249114.pdf; https://repository.ubn.ru.nl/handle/2066/249114; https://doi.org/10.1136/archdischild-2020-321426 ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1136/archdischild-2020-321426 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://repository.ubn.ru.nl//bitstream/handle/2066/249114/249114.pdf<br />https://repository.ubn.ru.nl/handle/2066/249114<br />https://doi.org/10.1136/archdischild-2020-321426 ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.3FFF75E7 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1136/archdischild-2020-321426
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => unknown
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ruslami, R.
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Gafar, F.
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Yunivita, V.
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Parwati, I.
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ganiem, A.R
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Aarnoutse, R.E.
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Wilffert, B.
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Alffenaar, J.C.
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Nataprawira, H.M.
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2022
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Archives of Disease in Childhood, 107, 1, pp. 70-77
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |